<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35386322</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2452-199X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioactive materials</Title>
          <ISOAbbreviation>Bioact Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>107</StartPage>
          <EndPage>119</EndPage>
          <MedlinePgn>107-119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2022.03.008</ELocationID>
        <Abstract>
          <AbstractText>The clinical outcomes of cancer nanovaccine have been largely impeded owing to the low antigen-specific T cell response rate and acquired resistance caused by the immunosuppressive tumor microenvironment (TME). Here, we reported a tumor acidity-responsive nanovaccine to remodel the immunosuppressive TME and expand the recruitment of tumor infiltrating lymphocytes (TILs) using hybrid micelles (HM), which encapsulated colony stimulating factor 1 receptor (CSF1-R) inhibitor BLZ-945 and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG-919 in its core and displayed a model antigen ovalbumin (OVA) on its surface (denoted as BN@HM-OVA). The bioactive nanovaccine is coated with a polyethylene glycol (PEG) shell for extending nanoparticle circulation. The shell can be shed in response to the weakly acidic tumor microenvironment. The decrease in size and the increase in positive charge may cause the deep tumor penetration of drugs. We demonstrated that the bioactive nanovaccine dramatically enhance antigen presentation by dendritic cells (DCs) and drugs transportation into M1-like tumor-associated macrophages (TAMs) and tumor cells via size reduction and increasing positive charge caused by the weakly acidic TME. Such bioactive nanovaccine could remodel the immunosuppressive TME into an effector T cells favorable environment, leading to tumor growth inhibition in prophylactic and therapeutic E.G7-OVA tumor models. Furthermore, combining the bioactive nanovaccine with simultaneous anti-PD-1 antibody treatment leads to a long-term tumor inhibition, based on the optimal timing and sequence of PD-1 blockade against T cell receptor. This research provides a new strategy for the development of efficient cancer immunotherapy.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Xiaoxue</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hanxi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Qingqing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Geng</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ningxi</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xiaodan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tingting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Chunhui</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xiaojuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biorheological Science and Technology, Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Guixue</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biorheological Science and Technology, Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yiyao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-qiao Road, Chengdu, 610072, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biophysics, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bioact Mater</MedlineTA>
        <NlmUniqueID>101685294</NlmUniqueID>
        <ISSNLinking>2452-199X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bioactive nanovaccine</Keyword>
        <Keyword MajorTopicYN="N">Cancer immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">IDO inhibitor</Keyword>
        <Keyword MajorTopicYN="N">TAMs</Keyword>
        <Keyword MajorTopicYN="N">TME</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35386322</ArticleId>
        <ArticleId IdType="pmc">PMC8958467</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioactmat.2022.03.008</ArticleId>
        <ArticleId IdType="pii">S2452-199X(22)00124-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C., Kim T.Y., Choo S.P., Trojan J., Welling T.H.R., Meyer T., Kang Y.K., Yeo W., Chopra A., Anderson J., Dela Cruz C., Lang L., Neely J., Tang H., Dastani H.B., Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7539326</ArticleId>
            <ArticleId IdType="pubmed">28434648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Dang F., Ren J., Wei W. Biochemical aspects of PD-L1 regulation in cancer immunotherapy. Trends Biochem. Sci. 2018;43(12):1014–1032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6252278</ArticleId>
            <ArticleId IdType="pubmed">30287140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P., Hu-Lieskovan S., Wargo J.A., Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5391692</ArticleId>
            <ArticleId IdType="pubmed">28187290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma V., Shrimali R.K., Ahmad S., Dai W., Wang H., Lu S., Nandre R., Gaur P., Lopez J., Sade-Feldman M., Yizhak K., Bjorgaard S.L., Flaherty K.T., Wargo J.A., Boland G.M., Sullivan R.J., Getz G., Hammond S.A., Tan M., Qi J., Wong P., Merghoub T., Wolchok J., Hacohen N., Janik J.E., Mkrtichyan M., Gupta S., Khleif S.N. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 2019;20(9):1231–1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7472661</ArticleId>
            <ArticleId IdType="pubmed">31358999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moffett J.R., Namboodiri M.A. Tryptophan and the immune response. Immunol. Cell Biol. 2003;81(4):247–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12848846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003;9(10):1269–1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selvan S.R., Dowling J.P., Kelly W.K., Lin J. Indoleamine 2,3-dioxygenase (Ido): biology and target in cancer immunotherapies. Curr. Cancer Drug Targets. 2016;16(9):755–764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26517538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12401408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67(11):5064–5066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17545580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W., Yang J., Luo L., Jiang M., Qin B., Yin H., Zhu C., Yuan X., Zhang J., Luo Z., Du Y., Li Q., Lou Y., Qiu Y., You J. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 2019;10(1):3349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6659660</ArticleId>
            <ArticleId IdType="pubmed">31350406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L., Li Y., Du Y., Zhang Y., Wang X., Ding Y., Yang X., Meng F., Tu J., Luo L., Sun C. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat. Commun. 2019;10(1):4871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6814770</ArticleId>
            <ArticleId IdType="pubmed">31653838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., Fein M., Rasch M.G., Tan Y.X., Qiu J., Park J., Sinha P., Bissell M.J., Frengen E., Werb Z., Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012;21(4):488–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3332002</ArticleId>
            <ArticleId IdType="pubmed">22516258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hume D.A., MacDonald K.P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119(8):1810–1820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22186992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott I., Scheffler H., Gust R. Development of a method for the quantification of the molar gold concentration in tumour cells exposed to gold-containing drugs. ChemMedChem. 2007;2(5):702–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17407197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao D., Ma X., Cai J., Luan J., Liu A.J., Yang R., Cao Y., Zhu X., Zhang H., Chen Y.X., Shi Y., Shi G.X., Zou D., Cao X., Grusby M.J., Xie Z., Zhang W.J. ZBTB20 is required for anterior pituitary development and lactotrope specification. Nat. Commun. 2016;7:11121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4835541</ArticleId>
            <ArticleId IdType="pubmed">27079169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spranger S., Spaapen R.M., Zha Y., Williams J., Meng Y., Ha T.T., Gajewski T.F. Up-regulation of PD-L1, Ido, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 2013;5(200):200ra116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136707</ArticleId>
            <ArticleId IdType="pubmed">23986400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma V., Shrimali R.K., Ahmad S., Dai W., Wang H., Lu S., Nandre R., Gaur P., Lopez J., Sade-Feldman M., Yizhak K., Bjorgaard S.L., Flaherty K.T., Wargo J.A., Boland G.M., Sullivan R.J., Getz G., Hammond S.A., Tan M., Qi J., Wong P., Merghoub T., Wolchok J., Hacohen N., Janik J.E., Mkrtichyan M., Gupta S., Khleif S.N. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 2019;20(11):1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31551574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu Y.L., Chen S.A., Chen J.H., Chen K.J., Chen H.L., Sung H.W. A dual-emission Forster resonance energy transfer nanoprobe for sensing/imaging pH changes in the biological environment. ACS Nano. 2010;4(12):7467–7474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21082810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X., Liu D.E., Wang T., Lu H., Ma J., Chen Q., Gao H. Aggregation-induced-emissive molecule incorporated into polymeric nanoparticulate as FRET donor for observing doxorubicin delivery. ACS Appl. Mater. Interfaces. 2015;7(42):23760–23766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26448180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie X., Chen Y., Chen Z., Feng Y., Wang J., Li T., Li S., Qin X., Wu C., Zheng C., Zhu J., You F., Liu Y., Yang H. Polymeric hybrid nanomicelles for cancer theranostics: an efficient and precise anticancer strategy for the codelivery of doxorubicin/miR-34a and magnetic resonance Imaging. ACS Appl. Mater. Interfaces. 2019;11(47):43865–43878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31684723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu D., Zhou J., Chen X., Chen Y., Hou S., Qian H., Zhang L., Tang G., Chen Z., Ping Y., Fang W., Duan H. Mesoporous polydopamine with built-in plasmonic core: traceable and NIR triggered delivery of functional proteins. Biomaterials. 2020;238:119847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32058869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 2012;12(4):265–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433802</ArticleId>
            <ArticleId IdType="pubmed">22437871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today. 1999;20(10):469–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10500295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Xia R., Huang Y., Zhao W., Li J., Zhang X., Wang P., Venkataramanan R., Fan J., Xie W., Ma X., Lu B., Li S. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat. Commun. 2016;7:13443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5103075</ArticleId>
            <ArticleId IdType="pubmed">27819653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molon B., Cali B., Viola A. T cells and cancer: how metabolism shapes immunity. Front. Immunol. 2016;7:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4740780</ArticleId>
            <ArticleId IdType="pubmed">26870036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paulis L.E., Mandal S., Kreutz M., Figdor C.G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 2013;25(3):389–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23571027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 2001;106(3):263–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11509174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dienz O., Rincon M. The effects of IL-6 on CD4 T cell responses. Clin. Immunol. 2009;130(1):27–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2660866</ArticleId>
            <ArticleId IdType="pubmed">18845487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J., Lv J., Zhuang Q., Yang Z., Cao Z., Xu L., Pei P., Wang C., Wu H., Dong Z., Chao Y., Wang C., Yang K., Peng R., Cheng Y., Liu Z. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat. Nanotechnol. 2020;15(12):1043–1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33139933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirstrom K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3203524</ArticleId>
            <ArticleId IdType="pubmed">22039576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian Y., Qiao S., Dai Y., Xu G., Dai B., Lu L., Yu X., Luo Q., Zhang Z. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small Interfering RNA to tumor-associated macrophages. ACS Nano. 2017;11(9):9536–9549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28858473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ries C.H., Cannarile M.A., Hoves S., Benz J., Wartha K., Runza V., Rey-Giraud F., Pradel L.P., Feuerhake F., Klaman I., Jones T., Jucknischke U., Scheiblich S., Kaluza K., Gorr I.H., Walz A., Abiraj K., Cassier P.A., Sica A., Gomez-Roca C., de Visser K.E., Italiano A., Le Tourneau C., Delord J.P., Levitsky H., Blay J.Y., Ruttinger D. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24898549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W., Liang P., Guo G., Huang Z., Niu Y., Dong L., Wang C., Zhang J. Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci. Rep. 2016;6:24506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4830950</ArticleId>
            <ArticleId IdType="pubmed">27074905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H., Moynihan K.D., Zheng Y., Szeto G.L., Li A.V., Huang B., Van Egeren D.S., Park C., Irvine D.J. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4069155</ArticleId>
            <ArticleId IdType="pubmed">24531764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 2005;5(8):617–628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16056255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Koker S., Cui J., Vanparijs N., Albertazzi L., Grooten J., Caruso F., De Geest B.G. Engineering polymer hydrogel nanoparticles for lymph node-targeted delivery. Angew Chem. Int. Ed. Engl. 2016;55(4):1334–1339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26666207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J., Liu X., Liao Y.P., Wang X., Ahmed A., Jiang W., Ji Y., Meng H., Nel A.E. Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the Ido-1 pathway. ACS Nano. 2018;12(11):11041–11061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6262474</ArticleId>
            <ArticleId IdType="pubmed">30481959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng J., Xiao Y., Li W., Yang Q., Tan L., Jia Y., Qu Y., Qian Z. Photosensitizer micelles together with Ido inhibitor enhance cancer photothermal therapy and immunotherapy. Adv. Sci. 2018;5(5):1700891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5979747</ArticleId>
            <ArticleId IdType="pubmed">29876215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A., Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 2015;212(4):435–445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387285</ArticleId>
            <ArticleId IdType="pubmed">25753580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baer C., Squadrito M.L., Laoui D., Thompson D., Hansen S.K., Kiialainen A., Hoves S., Ries C.H., Ooi C.H., De Palma M. Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity. Nat. Cell Biol. 2016;18(7):790–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27295554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., Olson O.C., Quick M.L., Huse J.T., Teijeiro V., Setty M., Leslie C.S., Oei Y., Pedraza A., Zhang J., Brennan C.W., Sutton J.C., Holland E.C., Daniel D., Joyce J.A. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013;19(10):1264–1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3840724</ArticleId>
            <ArticleId IdType="pubmed">24056773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q., Wang C., Zhang X., Chen G., Hu Q., Li H., Wang J., Wen D., Zhang Y., Lu Y., Yang G., Jiang C., Wang J., Dotti G., Gu Z. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 2019;14(1):89–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30531990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q., Xu L., Liang C., Wang C., Peng R., Liu Z. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 2016;7:13193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5078754</ArticleId>
            <ArticleId IdType="pubmed">27767031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stenger S., Hanson D.A., Teitelbaum R., Dewan P., Niazi K.R., Froelich C.J., Ganz T., Thoma-Uszynski S., Melian A., Bogdan C., Porcelli S.A., Bloom B.R., Krensky A.M., Modlin R.L. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 1998;282(5386):121–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9756476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Wu S., Qin Y., Fan F., Zhang Z., Huang C., Ji W., Lu L., Wang C., Sun H., Leng X., Kong D., Zhu D. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy. Nano Lett. 2019;19(7):4237–4249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30868883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowalczyk D.W., Wlazlo A.P., Giles-Davis W., Kammer A.R., Mukhopadhyay S., Ertl H.C. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther. 2003;10(12):870–878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14712313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasare C., Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol. 2003;15(6):677–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14630202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta. 2011;1813(5):878–888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21296109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim Y., Kang S., Shin H., Kim T., Yu B., Kim J., Yoo D., Jon S. Sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade effectively inhibits tumor growth and relapse. Angew Chem. Int. Ed. Engl. 2020;59(34):14628–14638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32430981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu G., Lynn G.M., Jacobson O., Chen K., Liu Y., Zhang H., Ma Y., Zhang F., Tian R., Ni Q., Cheng S., Wang Z., Lu N., Yung B.C., Wang Z., Lang L., Fu X., Jin A., Weiss I.D., Vishwasrao H., Niu G., Shroff H., Klinman D.M., Seder R.A., Chen X. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat. Commun. 2017;8(1):1954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5715147</ArticleId>
            <ArticleId IdType="pubmed">29203865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 2012;24(2):207–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319479</ArticleId>
            <ArticleId IdType="pubmed">22236695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008;26:677–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18173375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., Brahmer J.R., Lawrence D.P., Atkins M.B., Powderly J.D., Leming P.D., Lipson E.J., Puzanov I., Smith D.C., Taube J.M., Wigginton J.M., Kollia G.D., Gupta A., Pardoll D.M., Sosman J.A., Hodi F.S. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014;32(10):1020–1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4811023</ArticleId>
            <ArticleId IdType="pubmed">24590637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12(4):252–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
